Tumor Embolization: Embolization of Liver Tumors

  • Thuong G. Van Ha
Chapter

Abstract

With approximately one million deaths per year, liver cancer is the fourth leading cause of cancer-related deaths worldwide. The disease is, in general, lethal, with the mortality almost equaling its incidence. Hepatocellular carcinoma (HCC) usually arises in the setting of chronic liver disease or cirrhosis and is the most common cause of death in patients with compensated liver cirrhosis. Risks factors for the development of HCC includes hepatitis B carrier state, hepatitis C infection, hereditary hemochromatosis, and cirrhosis. Despite development of different treatment strategy, overall survival rates of HCC remain poor, with estimation of 54 % at 1 year, 40 % at 2 years, and 28 % at 3 years. In patients with late-stage diagnosis, the median survival is between 6 and 20 months.

Keywords

Hepatitis Sorafenib Tace Hemochromatosis Gelfoam 

References

  1. 1.
    El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol. 2002;35S:72–8.CrossRefGoogle Scholar
  2. 2.
    Munoz N, Bosch FX. Epidemiology of hepatocellular carcinoma. In: Okuda K, Ishak K, editors. Neoplasms of the liver. Tokyo: Springer; 1989. p. 3–19.Google Scholar
  3. 3.
    Eattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127(5 Suppl 1):S35–50.CrossRefGoogle Scholar
  4. 4.
    A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology. 1998;28:751–5.Google Scholar
  5. 5.
    Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of smallhepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP. Livertransplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl. 2002;8:765–74.PubMedCrossRefGoogle Scholar
  7. 7.
    Freeman Jr RB. Transplantation for hepatocellular carcinoma: The Milan criteria and beyond. Liver Transpl. 2006;12 Suppl 2:S8–13.PubMedCrossRefGoogle Scholar
  8. 8.
    Nakamura H, Hashimoto T, Oi H, Sawada S. Transcatheter oily chemoembolization for hepatocellular carcinoma. Radiology. 1989;170:783–6.PubMedGoogle Scholar
  9. 9.
    Venook AP, Stagg RJ, Lewis BJ, Chase JL, Ring EJ, Maroney TP, et al. Chemoembolization for hepatocellular carcinoma. J Clin Oncol. 1990;8:1108–14.PubMedGoogle Scholar
  10. 10.
    Bronowicki JP, Vetter D, Dumas F, et al. Transcatheter oily chemoembolization for hepatocellular carcinoma. A four-year study of 127 French patients. Cancer. 1994;74:16–24.PubMedCrossRefGoogle Scholar
  11. 11.
    Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluding bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33:41–52.PubMedCrossRefGoogle Scholar
  12. 12.
    Inarrairaegui M, Thurston KG, Bilbao JI, et al. Radioembolization with use of Yttrium-90 microspheres in patients with hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol. 2010;21:1205–12.PubMedCrossRefGoogle Scholar
  13. 13.
    Llovet JM, Real MI, Montana X, et al. Arterial embolization or chemoembolisation versus symptomatic treatments in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet. 2002;359:1734–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol. 2007;30:6–25.PubMedCrossRefGoogle Scholar
  15. 15.
    Chan AO, Yuen MF, Hui CK, et al. A prospective study regarding the complications of transcatheter arterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer. 2002;94:1747–52.PubMedCrossRefGoogle Scholar
  16. 16.
    Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.PubMedCrossRefGoogle Scholar
  17. 17.
    Kang SG, Yoon CJ, Jeong SH, et al. Single-session combined therapy with chemoembolization and radiofrequency ablation in hepatocellular carcinoma less than or equal to 5 cm: a preliminary study. J Vasc Interv Radiol. 2009;20:1570–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Cabibbo G, Latteri F, Antonucci M, Craxi A. Multimodal approaches to the treatment of hepatocellular carcinoma. Nat Clin Pract Gastroenterol Hepatol. 2009;6:159–69.PubMedCrossRefGoogle Scholar
  19. 19.
    Bruix J, Sherman M. Practice guidelines committee. American Association for the study of liver diseases. Management of hepatocellular carcinoma. J Hepatol. 2005;42:1208–36.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Thuong G. Van Ha
    • 1
  1. 1.Section of Vascular and Interventional Radiology, Department of RadiologyThe University of Chicago Medical CenterChicagoUSA

Personalised recommendations